Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry

Informations projet

Genome Biologics

N° de convention de subvention: 773750

DOI

10.3030/773750

Projet clôturé

Date de signature de la CE 12 Mai 2017

Date de début 1 Juin 2017

Date de fin 30 Septembre 2017

Financé au titre de

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

GENOME BIOLOGICS UG
Germany

Periodic Reporting for period 1 - Genome Biologics (Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry)

Période du rapport: 2017-06-01 au 2017-09-30

Résumé du contexte et des objectifs généraux du projet

Modern drug discovery is inefficient, expensive and risky. Due to high development costs, diseases with smaller market share, such as rare diseases are only satisfied in 5% of cases leaving nearly 350mln people worldwide without any treatments. The Genome Biologics GENIMAPS® and GENISYST® patented drug discovery and testing platform overcomes the inefficiencies of pre-clinical studies with its unique combination of genomics, molecular science and. Using our proprietary Artificial Intelligence-driven Drug-Disease matching platform (GENIMAPS®) and our patented single cell transgenic technology (GENISYST®), the platform reduces drug development or drug repurposing time and costs by a factor of 10, allowing pharmaceuticals companies to bring drug candidates into phase 2/3 clinical trials in as little as 3-6 months, instead of 7-10 years with current methodologies.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Out of the seventeen organisations contacted we have identified a strong interest in our technologies in multiple therapeutic areas, including cardiovascular disease (CVD), Central Nervous System disorders (CNS) and oncology (multiple indications and subtypes).
In addition, we have identified potential interest in our technologies for lifestyle diseases, including Non-Alcoholic Fatty Liver disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), obesity and diabetes, which we are currently following up with one of the potential trial partners for a future project application in Phase 2. Investigation of the regulatory environment within Europe has not revealed any issues apart from the requirement to obtain biosafety approval from the appropriate government biosafety authorities. We have provided price indications and quotations to a number of companies and the response has been very good. All companies see the benefit of our technologies outweighing the cost and therefore are not particularly sensitive to the cost factor. These and other analyses are summarised in the Phase 1 final report.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

In combining the power of our GENIMAPS and GENISYST platform, we have identified and developed 2 promising therapeutic agents for heart failure which demonstrated efficacy in restoring heart function and reducing mortality in rodent pre-clinical studies. If successful in downstream clinical trials, these compounds have the potential to alleviate heart disease in humans and increase life quality and expectancy. In parallel, Genome Biologics have discovered a potential for the repurposing of 5 FDA-approved compounds for the treatment of specific sub-types of prostate cancer in humans. Pending further studies, these compounds could contribute to better treatment options for prostate cancer.

Genome Biologics Technology Advantage